Navigation Links
Isis Initiates Phase 1 Study in Patients With Cancer With the First Generation 2.5 Antisense Drug, ISIS-STAT3Rx
Date:3/7/2012

said Brett Monia, Ph.D., Senior Vice President, Drug Discovery and Corporate Development at Isis.  "We are very excited about the potential of our Generation 2.5 STAT3 drug to treat human cancers with high unmet medical needs as we continue to be the leader in antisense innovation. The advancement of our first drug incorporating our new, more potent Generation 2.5 chemistry is a key milestone and should allow us to further extend the reach of our technology into new targets, new tissues, and new disease opportunities."

ISIS-STAT3Rx is the first Generation 2.5 drug in Isis' pipeline. It is designed to treat cancer by inhibiting the production of STAT3, a gene that blocks natural cell death and that is critical for tumor cell growth and survival.  Inhibition of STAT3 has been shown to block the induction of tumor-associated cytokines involved in the progression of cancer, such as IL-6, IL-1, TGFβ, and IL-10, which could serve as important biomarkers in clinical studies.  Analyses of these cytokines in Phase 1 could serve as an early indicator of anticancer activity of ISIS-STAT3Rx in patients with cancer.

ABOUT ISIS PHARMACEUTICALS, INC.
Isis is exploiting its leadership position in antisense technology to discover and develop novel drugs for its product pipeline and for its partners.  Isis' broad pipeline consists of 26 drugs to treat a wide variety of diseases with an emphasis on cardiovascular, metabolic, severe and rare diseases, and cancer.  Isis' partner, Genzyme, plans to commercialize Isis' lead product, KYNAMRO, following regulatory approval, which is expected in 2012.  Isis' patents provide strong and extensive protection for its drugs and technology.  Additional information about Isis is available at www.isispharm.com.

ISIS PHARMACEUTICALS' FORWARD-LOOKING STATEMENT
This press release includes forward-looking statements regardin
'/>"/>

SOURCE Isis Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. EntreMed Initiates Plans for China Office
2. American Regent Initiates Nationwide Voluntary Recall of Phenylephrine HCl Injection, USP, 1%, 5 mL Vial, Lot# 0693, Due to Visible Particles
3. Echo Therapeutics Initiates Clinical Trials of its Symphony tCGM System in Critical Care Patients
4. Sangart Initiates Phase 1b Study of MP4CO in Patients With Sickle Cell Disease
5. Merrimack Pharmaceuticals Initiates Enrollment in Phase 1 Study of MM-151 in Patients with Refractory Advanced Solid Tumors
6. Sumagen Initiates Clinical Testing of Omnia Biologics Manufactured HIV Vaccine
7. Pfizer Initiates Phase 1 Clinical Trial for FVIIa Hemophilia Drug Candidate Developed by Catalyst Biosciences
8. Zimmer Initiates Quarterly Dividend and Announces New Share Repurchase Program
9. Isis Initiates Phase 1 Clinical Study of ISIS-SMNRx in Patients With Spinal Muscular Atrophy
10. Soligenix Initiates Next Generation Anthrax Vaccine Development Program Under Agreement With Harvard University
11. Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Study of MM-121 in Combination with Cetuximab and Irinotecan in Patients with Advanced Cancers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/18/2013)... 18, 2013   Polymer Technology Systems, Inc. ... Health Group to integrate the CardioChek ® ... administered by health systems across the country. The ... and distributed through Hanson Medical Systems , ... cholesterol, LDL cholesterol, triglycerides, and glucose. ...
(Date:6/17/2013)... Texas , June 17, 2013  Hanger, Inc. ... 5-year credit agreement that increases its senior secured facilities ... $400 million previously.  The new credit agreement includes a ... term loan facility.  The previous credit agreement was comprised ... $300 million term loan.  Each new facility matures on ...
(Date:6/17/2013)... 2013 BioMed Realty Trust, Inc. (NYSE: ... declared a second quarter 2013 dividend of $0.235 per share ... dividend of $0.94 per common share. The ... stockholders of record at the close of business on June ... BioMed Realty delivers optimal real estate solutions for biotechnology ...
Breaking Medicine Technology:Polymer Technology Systems, Inc. to Provide Point-of-Care Lipid Testing to Aegis Health Group's Hospital Clients 2Polymer Technology Systems, Inc. to Provide Point-of-Care Lipid Testing to Aegis Health Group's Hospital Clients 3Hanger Enters New 5-Year Credit Agreement to Refinance Senior Secured Credit Facilities 2Hanger Enters New 5-Year Credit Agreement to Refinance Senior Secured Credit Facilities 3BioMed Realty Trust Declares Second Quarter 2013 Common Stock Dividend 2BioMed Realty Trust Declares Second Quarter 2013 Common Stock Dividend 3
... Jan. 28 Repligen Corporation (Nasdaq: RGEN ... with GE Healthcare Bio-Sciences AB by entering into a five-year ... the manufacture of monoclonal antibodies, a highly successful class of ... A and has manufactured recombinant Protein A for GE Healthcare ...
... , , , ... 9th year, the ePharma,Summit ( http://www.epharmasummit.com ), to be held ... PA ,continues to be the most,innovative digital marketing event ... from leading pharmaceutical,companies attend ePharma Summit for incomparable access to ...
Cached Medicine Technology:Repligen Announces Long Term Supply Agreement with GE Healthcare for Recombinant Protein A 2Repligen Announces Long Term Supply Agreement with GE Healthcare for Recombinant Protein A 3MarketsandMarkets Partners with the 9th Annual ePharma Summit to be Held on February 8 -10, 2010 2MarketsandMarkets Partners with the 9th Annual ePharma Summit to be Held on February 8 -10, 2010 3
(Date:6/18/2013)... (PRWEB) June 18, 2013 David Connett, ... of Family Medicine for the College of Osteopathic Medicine ... Sciences has been elected president of the Osteopathic ... G. Brown Jr. appointed Connett, a 1984 alumnus of ... members recently elected Connett to the position during a ...
(Date:6/18/2013)... the mammary gland appear to provide a crucial link ... and the subsequent development of breast cancer, researchers from ... issue of the journal Cancer Prevention Research . ... with an increased risk of certain types of aggressive ... social stress to cancer have been hard to identify. ...
(Date:6/18/2013)... discovered a way to make phytosterol molecules from plants ... humans, potentially opening the way to dramatic reductions in ... the new process and composition was issued on June ... molecules in animals are highly similar and when both ... When they mix in the gut of an animal, ...
(Date:6/18/2013)... fitness training system using a person,s DNA was ... the LeWeb,13 London Startup Competition, Europe,s largest technology ... Genetrainer, building on University of Bristol research by ... Julian Gough, Professor of Bioinformatics in the University,s ... 350 startups to be one of 16 finalists ...
(Date:6/18/2013)... 2013 Dr. Farooq Ashraf, an Atlanta ... Institute, is pleased to announce that he is offering ... LASIK equipment, the iFS™ Advanced Femtosecond Laser. Currently, the ... Atlanta to offer its patients this new technology, and ... patients a complimentary upgrade to the Advanced Femtosecond Laser. ...
Breaking Medicine News(10 mins):Health News:Fat cells in breast may connect social stress to triple-negative breast cancer 2Health News:Fat cells in breast may connect social stress to triple-negative breast cancer 3Health News:Fat cells in breast may connect social stress to triple-negative breast cancer 4Health News:Brandeis scientist invents anti-cholesterol process 2Health News:Atlanta LASIK Surgeon Offers New LASIK Technology 2
... arrests and then receive coronary angiography are twice as ... those who don,t have the procedure, according to a ... The study, published in the May/June issue of the ... available online, showed that patient outcomes improved with coronary ...
... expensive treatment laterHARRISBURG, Pa., March 31 As the ... their expenses, the Pennsylvania Dental Association (PDA) is stressing ... up with their oral health care."The PDA understands how ... ends meet in economic hard times, especially those facing ...
... 31 Dynatronics Corporation (Nasdaq: DYNT ) ... period extension with the SEC, giving the company until ... per share minimum bid rule."We are pleased that NASDAQ ... H. Cullimore Jr., chairman and president of Dynatronics. "This ...
... packages barrage consumers with information, some required to ... brand names still overshadow critical fine print on ... , In a study to be published in ... Science , MSU researchers examined the effectiveness of ...
... Cold Spring Harbor Laboratory (CSHL) and 20 other major research ... challenge to the neuroscience community. At long last, the ... assemble a comprehensive map of the major neural circuits in ... genomes of many organisms, including that of humans, have been ...
... Surgery 2008 Procedural Survey shows a 2% decrease in ... time in several years, male cosmetic surgery has declined ... Surgery (AACS), a leader in the cosmetic surgery industry, ... that males are cutting back on cosmetic procedures. ...
Cached Medicine News:Health News:Coronary angiography may improve outcomes for cardiac arrest patients 2Health News:Coronary angiography may improve outcomes for cardiac arrest patients 3Health News:Pennsylvania Dental Association Cautions Patients: Don't Forgo Dental Visits Because of the Economy 2Health News:NASDAQ Gives Dynatronics a Third Three-Month Extension for Minimum Bid Price Compliance 2Health News:Researchers question effectiveness of warning labels on over-the-counter drugs 2Health News:Researchers question effectiveness of warning labels on over-the-counter drugs 3Health News:CSHL neuroscientists propose project to comprehensively map mammalian brain circuits 2Health News:CSHL neuroscientists propose project to comprehensively map mammalian brain circuits 3Health News:CSHL neuroscientists propose project to comprehensively map mammalian brain circuits 4Health News:CSHL neuroscientists propose project to comprehensively map mammalian brain circuits 5Health News:Male Cosmetic Surgery Slows Down While Female Cosmetic Surgery Advances 2
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Large type 1/1 (mm), opening width 10.0 mm and length 10 mm....
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Large type 1/1 (mm), opening width 8.0 mm and length 6 mm....
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Large type 1/1 (mm), opening width 7.0 mm and length 7.7 mm....
Extremely wide blade opening. Excellent bio and MRI compatibility. Lot number on each clip. Long reliable history. Large type 1/1 (mm), opening width 9.0 mm and length 7.5 mm....
Medicine Products: